Andrew is joined by Nick Karos, Chief Executive Officer / Director of Capital Markets from Universal Ibogaine. TSX.V: IBO

January 26, 2022

Universal Ibogaine Enters Drug Supply Agreement Calgary, AB – January 26, 2022 – Universal Ibogaine Inc. (TSXV:IBO) (“UI” or the “Company”) a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, is pleased to advise it has entered into an agreement (the “agreement”) with Psygen Labs Inc. (“Psygen”) to secure a supply of GMP ibogaine for use in its planned future clinical trial for opioid use disorder and ongoing ibogaine detox treatments at its clinics.


As Director of Capital Markets, Nick Karos is a seasoned financier based in Los Angeles. His background includes senior roles with US investment banks and as CEO of Private Trading Group. Mr. Karos is focused on expanding awareness of UI in the US-based investment community including institutional investors, family offices, high net worth individuals and investment advisors, securing sources of expansion capital, as well as identifying business development opportunities in the addiction treatment industry.


Our Mission Our mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery. While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.


Our goal is to help you feel comfortable stepping into the stock market and are giving you free hot tips every day!



Join us on twitter to get our DAILY live video market updates @chargingstocks